Pantginis Reiterates Buy on Nuvectis, Citing Ciprocopan Approval and Pipeline Diversification; Price Target Maintained at $39Tip Ranks·1 day ago, 10:25 AMNVCT-4.17%
Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement InhibitorsUnusual Whales·1 day ago, 06:33 AMNVCT-4.17%
Nuvectis says China regulator approves ciprocopan for treatment-naive PNH patientsPUBT·1 day ago, 06:32 AMNVCT-4.17%002653-8.19%
China's Haisco Gets China’s Nod for Rare Blood Disorder DrugYicai·1 day ago, 06:27 AM002653-8.19%NVCT-4.17%
The Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rushbusinessinsider·Jul 9 at 06:45 AMNVCT-4.17%
Insiders Make Bold Move as Nuvectis Pharma Leadership Ramps Up Buying SpreeTip Ranks·Jul 1 at 09:04 PMNVCT-4.17%
Nuvectis Pharma Chairman, CEO Ron Bentsur buys USD 250,000 common sharesPUBT·Jul 1 at 12:40 PMNVCT-4.17%
Nuvectis Pharma Sets 5M-Share, $20 Offering; ~$93M Net, Cantor Fitzgerald UnderwriterTradingView·Jun 30 at 03:53 PMNVCT-4.17%
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga_article·Jun 30 at 07:05 AMUPC-10.55%DCOY+2.02%
Concentrix Reports Downbeat Q2 Earnings, Joins Nuvectis Pharma, Vishay Intertechnology And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Sessionbenzinga_article·Jun 30 at 07:03 AMMAMA+1.49%CNXC+3.10%
Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock | NVCT Stock NewsStockTitan·Jun 29 at 01:30 PMNVCT-4.17%
